Welcome to our dedicated page for Synaptogenix news (Ticker: SNPX), a resource for investors and traders seeking the latest updates and insights on Synaptogenix stock.
Synaptogenix Inc (SNPX) is a clinical-stage biopharmaceutical company advancing novel therapies for neurodegenerative disorders through its pioneering bryostatin research. This page serves as the definitive source for verified updates on clinical trials, regulatory developments, and scientific partnerships.
Investors and researchers will find comprehensive coverage of the company's progress in Alzheimer's research, multiple sclerosis studies, and orphan drug designations. Key updates include bryostatin-1 trial milestones, strategic academic collaborations, and intellectual property developments.
Our curated news collection features essential updates across three core areas: clinical trial advancements in cognitive disorders, research partnerships with leading neuroscience institutions, and regulatory progress for experimental therapies. This centralized resource eliminates the need to track multiple sources for critical developments.
Bookmark this page for real-time access to Synaptogenix's scientific breakthroughs and business updates. For comprehensive investment research, visit regularly to stay informed about this innovative leader in neurodegenerative disease therapeutics.
Synaptogenix (NASDAQ: SNPX) has formed an independent Special Committee to explore strategic opportunities for value creation. The company reports $19.6 million in cash as of September 30, 2024, with approximately 1.3 million common shares outstanding. The company expects a significant reduction in cash burn rate as it explores alternatives to previous R&D programs.
Synaptogenix is open to advancing its Bryostatin-1 asset through collaboration with a strategic partner offering non-dilutive investment. The company has also submitted a grant proposal to the National Institutes of Health (NIH) for Bryostatin-1 development.
Synaptogenix (NASDAQ: SNPX) has secured a $5.0 million financing through a combination of a registered public offering and a private placement. The company is selling 5,000 shares of newly issued Series C convertible preferred stock at $1,000 per share, convertible into common stock. The offering includes unregistered common stock purchase warrants and is expected to close around September 12, 2024.
Key details of the financing:
- Initial conversion price of $4.00 per share for Series C preferred stock
- 5.0% quarterly dividend payable in cash
- Warrants have an initial exercise price of $4.00 per common share
- Warrants are exercisable immediately and for five years from issuance
CEO Dr. Alan Tuchman stated that this capital will enhance the company's ability to explore potential acquisitions and fund research on innovative assets to drive growth and maximize shareholder value.
Synaptogenix (NASDAQ: SNPX) has announced a new collaboration with LSU Health New Orleans' Neuroscience Center of Excellence to test its polyunsaturated fatty acid (PUFA) analogs for treating spinal cord injury (SCI). The company also received US Patent No. 12,016,837 for its PUFA analogs in treating neurodegenerative diseases.
The study will compare these analogs with Bryostatin in SCI treatment. Synaptogenix holds exclusive rights to these PUFA analogs, which have shown promise in earlier pre-clinical testing for various neurodegenerative diseases. Like Bryostatin-1, these analogs activate the enzyme PKC epsilon (PKC ε), but at a different site, potentially offering a next-generation treatment for neurodegenerative conditions.
Synaptogenix has received FDA authorization for an Investigational New Drug (IND) application to conduct a clinical trial on Bryostatin-1, a potential treatment for multiple sclerosis (MS).
The trial, which will be held at the Cleveland Clinic Neurological Institute's Mellen Center, aims to evaluate the drug's effects on synaptic health and cognitive function using advanced 7-tesla MRI technology.
Synaptogenix highlights the need to address cognitive decline in MS, with the trial fully funded and expected to start soon.
Preclinical data shows that Bryostatin-1 may enhance synapse health, reduce inflammation, and prevent neurological degradation.
Synaptogenix has a strong financial position with $26.3 million in cash, supporting ongoing and future research efforts.
Synaptogenix, Inc. (Nasdaq: SNPX) praises the DEA's proposal to reclassify cannabis as a Schedule III drug, potentially benefitting its partner Cannasoul for cannabinoid-based drug discovery. The move would de-risk drug development, streamline regulatory pathways, and enhance clinical development for cannabis-based therapeutics.
